An application made for this job — a tailored resume and cover letter that speak straight to the posting.
Merck Ireland is seeking a Bioprocess Associate (Drug Substance) at Dundalk to join a fast-growing site focused on patient outcomes and safety. You will work within a cutting-edge, single-use facility and contribute to cGMP-compliant operations across DS/USP/DSP processes.
The role involves SOPs, PBRs, logbooks, OJT, and training, with a shift pattern transitioning to 4 cycle 12/7. A strong GMP background and biopharma experience are essential for success.
An exciting opportunity a Bioprocess Associate (Drug Substance) has arisen at our Dundalk manufacturing facility, you will be a key member of our fast-growing, dynamic startup, working with cutting-edge technology.
This role is focused on delivering to the patient through living the Dundalk culture, including a commitment to safety, focusing on right first time in everything we do, and concentrating on the engagement and development of self and peers.
The role is currently on Days but will transition to 4 cycle 12/7.
Within our Company in Ireland, we work at the forefront of science and technology to advance manufacturing excellence and R&D across our Irish sites and global company network. We're always looking to make a difference for people, patients, and communities - from our Company in Ireland to the world.
Ireland is one of the Ireland's leading healthcare companies, having first established here over 50 years ago. We have a dynamic and team of over 3,000 employees currently working across seven sites in Ballydine, Co Tipperary, Brinny, Co Cork, Dunboyne, Co Meath, Carlow, and Dublin, where, in addition, operate substantial Human Health and Animal Health businesses. Through our long-standing footprint in Ireland and over $6 billion invested across our Irish operations, our Irish sites manufacture many of our Company's top products, helping save and enhance lives in over 140 countries around the world.
As a cutting-edge, state-of-the-art vaccines facility spanning over 15,500 square metres across three stories, our Dundalk site will focus on qualification, continued product development and expanding its capabilities within our network. Featuring drug substance manufacturing, drug product manufacturing and quality control labs that will support the global supply of vaccine products - strengthening our ability to make an impact on people and patients worldwide by adding new capabilities to our already industry-leading network
We keep the patient at the very heart of all that we do and strive to find solutions and treatments for some of the world's most challenging healthcare needs.
As an equal opportunity